Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUST: +61 294230881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Wide moat miner looking to shift focus
Investors cheered an increased dividend but still heavily dependent on iron ore.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,238.70 | 21.50 | 0.23% |
| CAC 40 | 8,378.61 | 17.15 | 0.21% |
| DAX 40 | 25,141.16 | 142.76 | 0.57% |
| Dow JONES (US) | 49,533.19 | 32.26 | 0.07% |
| FTSE 100 | 10,619.43 | 63.26 | 0.60% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,578.38 | 31.71 | 0.14% |
| Nikkei 225 | 57,143.84 | 577.35 | 1.02% |
| NZX 50 Index | 13,247.02 | 215.40 | 1.65% |
| S&P 500 | 6,843.22 | 7.05 | 0.10% |
| S&P/ASX 200 | 9,007.00 | 12.80 | 0.14% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |